Detect biomarkers associated with Nonalcoholic Fatty Liver Disease (NAFLD)

Using the SomaScan® Assay to identify new biomarkers in liver disease

Abstract

In this 1-hour discussion, learn how the SomaScan Assay can be used to detect biomarkers associated with NAFLD—specifically, the identification of circulating proteins associated with fibrosis in NAFLD using a custom 5k-plex SomaScan Assay. Also discussed is the importance of identifying non-invasive biomarkers that improve clinical decision-making and drug development for NAFLD, and the strategies for multiplexed validation of candidate biomarkers discovered using the SomaScan Assay.

KC-picture-1-300x300

Kathleen Corey, MD, MPH, MMSc

Director of the Massachusetts General Hospital NAFLD program and an Assistant Professor of Medicine at Harvard Medical School

RPitts-002-2-300x300

Rebecca Pitts

Principal scientist at the Novartis Institutes for BioMedical Research in Cambridge, Massachusetts

 

Advancing biomarkers for Nonalcoholic Fatty Liver Disease using proteomics

A webinar presented by Kathleen Corey, MD, MPH, MMSc, and Rebecca Pitts


Share with colleagues

More webinars

WebinarUsing plasma proteomics to understand Alzheimer’s and other brain diseases

Dr. Walker discusses how he integrates proteomic, genetic, brain imaging and cerebral spinal fluid biomarkers from initially cognitively normal individuals who later develop dementia, in order to discover novel blood-based biomarkers and mechanistically relevant proteins for therapeutic target prioritization.

Learn more

WebinarProteomics for precision neuroscience: the power of protein analysis

This webcast highlights how academic, industry and government researchers are directly measuring protein abundance and function via multiplex proteomics to build more detailed characterizations of the biological systems underlying neurodegenerative diseases.

Learn more

WebinarCorrelation of a Nonalcoholic Steatohepatitis Proteomic Test with Clinical Outcomes

In this webinar, Anne Minnich, PhD, biomarker consultant at Bristol Myers Squibb, presents research on the use of the new SomaSignal(TM) NASH bundle test in a recently completed clinical trial.

Learn more